Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pathological Response Adapted Decision-making of Postoperative Management for HNSCC Receiving Induction Immunotherapy and Chemotherapy

NCT05777824 is registered in ClinicalTrials.gov with Cancer Institute and Hospital, Chinese Academy of Medical Sciences as lead sponsor.

NCT NCT05777824
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05777824 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pathological Response Adapted Decision-making of Postoperative Management for HNSCC Receiving Induction Immunotherapy and Chemotherapy
Lead sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase
Phase 2
Overall status
Recruiting
Start date
January 1, 2023
Completion date
December 30, 2027
Enrollment
84 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer